New drug shows promise for rare Muscle-Wasting disease
NCT ID NCT06411912
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental drug called NIDO-361 in 54 men with spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease. The goal was to see if the drug is safe and can help maintain or improve muscle mass. Participants received either the drug or a placebo, and researchers measured changes in muscle volume and tracked any side effects over about a year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KENNEDY'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedale Università di Padova
Padova, Italy
-
IRCCS Istituto Neurologico Carlo Besta
Milan, Italy
-
Kyungpook National University Chilgok Hospital
Daegu, South Korea
-
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center
Copenhagen, Denmark
-
University of College London Hospital (UCLH)
London, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.